Technetium (Tc) Labeled Radiopharmaceuticals Practice Test

Tc mertiatide, commonly known as MAG-3, is administered intravenously. This method of administration is essential for radiopharmaceuticals like MAG-3 because it allows for rapid distribution of the tracer throughout the vascular system. Intravenous administration ensures that the technetium-labeled compound reaches the target organs, specifically the kidneys, in an efficient and controlled manner, which is crucial for accurate imaging and assessment of renal function.

Magnetic Resonance Imaging (MRI) and other imaging modalities require the radiopharmaceutical to be in the bloodstream to visualize organ function and anatomy effectively. By administering MAG-3 intravenously, clinicians can achieve optimal imaging results while minimizing patient discomfort and maximizing tracer availability at the site of interest.